en.wikipedia.org/wiki/23andMe
1 correction found
TTAM completed the acquisition of substantially all of 23andMe's assets—including the Personal Genome Service, Research Services, and Lemonaid Health—on July 14, 2025.
Lemonaid Health was not part of what TTAM actually acquired on July 14, 2025. Official filings say the July closing covered 23andMe’s Personal Genome Service and Research Services, while Lemonaid remained with the bankruptcy estate and was later sold separately.
Full reasoning
This sentence overstates what closed on July 14, 2025.
Official 23andMe/TTAM materials for the closing say TTAM completed the acquisition of only the Personal Genome Service (PGS) and Research Services business lines. They do not say Lemonaid Health was included in the completed July 14 closing.
The SEC filing is even more explicit: after the July 14 sale, the company stated that its telehealth business continued to operate through its subsidiary, that it planned to sell Lemonaid Health, and that Lemonaid was part of the excluded business/assets. A later SEC filing then says Lemonaid remained owned by the debtors after the TTAM closing and was later the subject of a separate sale agreement with Bambumeta Ventures in September 2025.
So the inaccurate part of the claim is the inclusion of "Lemonaid Health" in what TTAM completed acquiring on July 14, 2025. The July 14 closing covered the core genetics/research businesses, while Lemonaid was handled separately afterward.
3 sources
- TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets | 23andMe Media Center
TTAM ... announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services business lines of 23andMe Holding Co.
- 23andMe Holding Co. Form 10-Q for quarter ended June 30, 2025
On July 14, 2025 ... the (a) direct-to-consumer genetic testing ... (PGS) and (b) research services business ceased to be included in the Company’s operations. The Company continues to operate its telehealth business through its subsidiary. The Company plans to sell Lemonaid Health, Inc.
- Chrome Holding Co. Form 8-K dated September 10, 2025
As previously disclosed, on July 14, 2025, the Debtors sold substantially all of their assets to 23andMe Research Institute ... The Debtors' Lemonaid telehealth business ... remains owned by the Debtors. ... the Company received a higher and better offer from Bambumeta Ventures ... to acquire Lemonaid Health.